Gelexir Healthcare, creator of a non-surgical procedure for the treatment of chronic lower back pain, has secured investments totalling £353,102. Investors in the Manchester University spin-out include Manchester University, the North West Fund for Biomedical managed by SPARK Impact (the fund allocates money from the European Regional Development Fund and the European Investment Bank), Central Manchester Foundation Trust and Business Angels.

Gelexir is based on discoveries and developments made at the university over the past 10 years by Tony Freemont,…